Radioimmunotherapy with 90Y anti-CD66 antibody for myeloablation prior to stem cell transplantation
Doctors and researchers from the Department of Internal Medicine III (Haematology, Oncology, Palliative Medicine, Rheumatology and Infectious Diseases) and Nuclear Medicine at Ulm University Hospital have successfully resumed their radioimmunotherapy programme (RIT) in accordance with §13.2b AMG. RIT with 90Y-labelledanti-CD66 antibodies offers the unique advantage that a very high level of irradiation of the bone marrow for myeloablation takes place before stem cell transplantation in haematological malignancies such as myelodysplastic syndrome and acute myeloid leukaemia. The initial experiences with patients are extremely encouraging.
Figure 1: Dosimetry image of an MDS patient (posterior view) taken 24 hours after injection of 99mTc-labelledanti-CD66 antibody showing intense uptake in the bone marrow (A). The corresponding bremsstrahlung image taken 24 hours after RIT with 90Y-labelledanti-CD66 antibody confirms high uptake of the radiolabelled antibody in the bone marrow (B). Weak tracer uptake is also seen in the liver and spleen, while the kidney shows no relevant uptake. Dosimetry based on PBPK modelling correctly predicted the dose delivered to the bone marrow.
